Condition

Fallopian Tube Cancer clinical trials and research

• 47Clinical trials
• 1New in 30 days
• 39Countries

Newest Fallopian Tube Cancer clinical trials

All recruiting trials (47)

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

• Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer

  This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586826

• Combining olaparib with cisplatin HIPEC during interval cytoreductive surgery for ovarian cancer

  This study will test whether giving the PARP inhibitor olaparib around interval cytoreductive surgery with heated intraperitoneal cisplatin (HIPEC) is safe and feasible for adults with advanced high‑grade serous ovarian or fallopian tube cancer who responded to neoadjuvant chemotherapy.

  Recruiting Phase 1/2 The Netherlands Cancer Institute · Amsterdam · NCT07460180

• AZD5335 given with itraconazole for ovarian, fallopian tube, and primary peritoneal cancer

  This trial will test whether the antifungal itraconazole changes how the investigational drug AZD5335 is processed in the body for people with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 6 sites Phase 1 AstraZeneca · Batumi and 8 other locations · NCT07402915

• IMGN151 alone or with carboplatin, olaparib, or bevacizumab for adults with high-grade serous gynecologic cancers

  This trial tests whether IV IMGN151, given alone or with carboplatin, olaparib, or bevacizumab, can reduce disease activity and be safely tolerated in adults with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 21 sites Phase 2 AbbVie · Los Angeles, California and 20 other locations · NCT07024784

• Personalized timing for interval debulking surgery in advanced ovarian cancer

  This study will test whether timing interval debulking surgery based on the CA125 drop (KELIM) after neoadjuvant chemotherapy helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer have better surgical outcomes than usual care.

  Recruiting Phase 2 The University of Hong Kong · Guangzhou and 5 other locations · NCT07023484

• Personalized timing of interval debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

  This study will see if using the CA125 drop rate (KELIM) to decide when to do interval debulking surgery helps people with advanced ovarian, fallopian tube, or peritoneal cancer who are receiving neoadjuvant chemotherapy.

  Recruiting Phase 2 The University of Hong Kong · Hong Kong · NCT07022535

• BL-B01D1 versus doctor‑chosen chemotherapy for platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This tests whether BL-B01D1 works better than the doctor’s choice of chemotherapy for adults with platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06994195

• IMNN-001 combined with standard chemotherapy for newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This trial tests whether adding IMNN-001 (an intraperitoneal IL-12 plasmid therapy) to standard paclitaxel/carboplatin chemotherapy helps people with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 10 sites Phase 3 Imunon · Orlando, Florida and 9 other locations · NCT06915025

• Combination treatment for advanced ovarian cancer

  This study is testing a new combination of medications for people with advanced ovarian cancer to see if it helps them feel better and stay healthier longer.

  Recruiting at 49 sites Phase 2 Corcept Therapeutics · Birmingham, Alabama and 48 other locations · NCT06906341

• Combining carboplatin with mirvetuximab soravtansine before surgery for FRα-positive advanced serous ovarian, fallopian tube, or primary peritoneal cancer

  This will test whether giving mirvetuximab soravtansine with carboplatin before surgery helps people with newly diagnosed FRα-positive advanced-stage serous ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 71 sites Phase 2 AbbVie · Birmingham, Alabama and 72 other locations · NCT06890338

• Cirtuvivint plus Olaparib for BRCA/HRD-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

  We will test whether adding cirtuvivint to daily olaparib is safe and tolerable for women with BRCA- or HRD-positive, platinum-resistant high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 2 sites Phase 1 University of Colorado, Denver · Aurora, Colorado and 1 other locations · NCT06856499

• Testing PHST001 for advanced solid tumors

  This study is testing a new treatment called PHST001 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 20 sites Phase 1 Pheast Therapeutics · Beverly Hills, California and 19 other locations · NCT06840886

• Evaluating a new treatment for recurrent ovarian cancer

  This study is testing a new treatment for women with recurrent ovarian cancer to see if it helps them live longer and feel better compared to standard care.

  Recruiting at 201 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 201 other locations · NCT06824467

• Evaluating SIM0505 for advanced solid tumors

  This study is testing a new treatment called SIM0505 to see if it is safe and effective for adults with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 6 sites Phase 1 NextCure, Inc. · Orlando, Florida and 16 other locations · NCT06792552

• Ubamatamab alone and with other cancer drugs for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

  This trial will test whether ubamatamab by itself or combined with bevacizumab, cemiplimab, fianlimab, or pegylated liposomal doxorubicin helps adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 56 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 55 other locations · NCT06787612

• Fluzoparib with or without Bevacizumab for treating advanced ovarian cancer

  This study is testing whether a new drug called Fluzoparib, alone or with another drug called Bevacizumab, can help people with advanced ovarian cancer caused by BRCA1/2 mutations do better than standard chemotherapy.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT06735326

• Evaluating TORL-1-23 for advanced platinum-resistant ovarian cancer

  This study is testing a new treatment called TORL-1-23 for women with advanced ovarian cancer that doesn't respond to standard platinum-based therapies to see if it can help them.

  Recruiting at 66 sites Phase 2 TORL Biotherapeutics, LLC · Phoenix, Arizona and 65 other locations · NCT06690775

• Immune cell therapy for recurrent ovarian cancer

  This study is testing a new immune cell therapy called 27T51 to see if it can help women with recurrent ovarian cancer feel better and fight their disease.

  Recruiting at 5 sites Phase 1 Regeneron Pharmaceuticals · Boston, Massachusetts and 4 other locations · NCT06469281

• Using blood volume management during surgery for ovarian cancer patients

  This study tests if a blood management technique called acute normovolemic hemodilution can help women with advanced ovarian cancer during surgery by reducing the need for blood transfusions and improving safety.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06290193

• Evaluating Sovilnesib for Ovarian Cancer Treatment

  This study is testing a new drug called sovilnesib to see if it can safely help people with a tough type of ovarian cancer that doesn't respond to standard treatments.

  Recruiting at 4 sites Phase 1 Volastra Therapeutics, Inc. · Birmingham, Alabama and 10 other locations · NCT06084416

• Comparing two types of sutures for vaginal cuff closure in laparoscopic hysterectomy

  This study is testing whether a new type of suture can close the vaginal cuff faster than a standard suture for women having laparoscopic hysterectomy, without causing more complications.

  Recruiting at 2 sites Aesculap AG · Frankfurt am Main, Hesse and 1 other locations · NCT06024109

• HS-20089 treatment for ovarian and endometrial cancer

  This study is testing a new treatment called HS-20089 to see if it can help people with recurrent or advanced ovarian and endometrial cancer feel better.

  Recruiting at 26 sites Phase 2 Hansoh BioMedical R&D Company · Hefei, Anfei and 27 other locations · NCT06014190

• Registry development for patients with gynecologic cancer in Korea

  This study is collecting information from women with gynecologic cancers in Korea to see how their treatments and outcomes can be improved.

  Recruiting Asan Medical Center · Seoul · NCT05912972

• Combination therapy using Mirvetuximab Soravtansine and Olaparib for ovarian cancer maintenance

  This study is testing a new combination treatment with Mirvetuximab Soravtansine and Olaparib to see if it helps women with certain types of recurrent ovarian cancer stay healthy after their initial treatment.

  Recruiting at 6 sites Phase 2 University of Colorado, Denver · Irvine, California and 5 other locations · NCT05887609

• Treatment of advanced solid tumors with AVZO-021

  This study is testing a new oral medication called AVZO-021 to see if it can safely help people with advanced solid tumors, especially certain types of breast cancer and other cancers with specific genetic changes.

  Recruiting at 13 sites Phase 1/2 Avenzo Therapeutics, Inc. · New Haven, Connecticut and 12 other locations · NCT05867251

• Adding IMNN-001 to chemotherapy for advanced ovarian cancer

  This study is testing if adding a new treatment called IMNN-001 to standard chemotherapy can help people with advanced ovarian cancer do better than with chemotherapy alone.

  Recruiting at 2 sites Phase 1/2 Imunon · Baltimore, Maryland and 3 other locations · NCT05739981

• Testing Rinatabart Sesutecan for advanced solid tumors

  This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.

  Recruiting at 67 sites Phase 1/2 Genmab · Phoenix, Arizona and 66 other locations · NCT05579366

• Characterizing ovarian cancer patients based on genetic factors

  This study looks at how genetic factors affect the treatment responses of women with ovarian cancer to see if they respond differently to standard chemotherapy over time.

  Recruiting Nordic Society of Gynaecological Oncology - Clinical Trials Unit · København Ø, Region Sjælland · NCT05574673

• Comparing 3 vs. 6 cycles of chemotherapy followed by niraparib for advanced ovarian cancer

  This study is testing whether having 3 or 6 cycles of chemotherapy followed by a drug called niraparib can help people with advanced ovarian cancer stay cancer-free longer.

  Recruiting at 31 sites Phase 2 North Eastern German Society of Gynaecological Oncology · Innsbruck and 49 other locations · NCT05460000

• Comparing stress reduction methods to standard care for ovarian cancer patients

  This study is testing if a mix of medications and therapies can help reduce stress in women with advanced ovarian cancer before their surgery, compared to those getting standard care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05429970

• Testing a new drug called XMT-1660 for solid tumors

  This study is testing a new drug called XMT-1660 to see if it is safe and effective for people with hard-to-treat solid tumors like triple negative breast cancer and ovarian cancer.

  Recruiting at 26 sites Phase 1/2 Day One Biopharmaceuticals, Inc. · Phoenix, Arizona and 25 other locations · NCT05377996

• Evaluating a new surgical approach to reduce ovarian cancer risk in high-risk women

  This study is testing a new surgery to see if removing fallopian tubes now and delaying ovary removal later can help women with BRCA1/2 gene mutations lower their risk of ovarian cancer just as well as the usual surgery.

  Recruiting at 11 sites M.D. Anderson Cancer Center · Chicago, Illinois and 10 other locations · NCT05287451

• Evaluating Olvi-Vec with chemotherapy for advanced ovarian cancer

  This study is testing if a new virus-based treatment called Olvi-Vec, combined with chemotherapy, can help women with tough-to-treat advanced ovarian cancer live longer and feel better.

  Recruiting at 33 sites Phase 3 Genelux Corporation · Mobile, Alabama and 32 other locations · NCT05281471

• Hepato-celiac lymphadenectomy for survival in primary or relapsed ovarian-related cancers

  This trial will try hepato-celiac lymphadenectomy to see if removing hepato-celiac lymph nodes helps adults with advanced or platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer that has spread to those nodes.

  Recruiting Shanghai Gynecologic Oncology Group · Shanghai · NCT05236686

• Combining surgery with targeted therapy for advanced ovarian cancer treatment

  This study is testing the best timing for surgery combined with targeted treatments to see if it helps people with advanced ovarian cancer feel better and live longer.

  Recruiting at 9 sites Phase 2 Shanghai Gynecologic Oncology Group · Foshan and 8 other locations · NCT05200260

• Adaptive chemotherapy approach for relapsed ovarian cancer

  This study is testing if adjusting the dose of carboplatin based on a blood marker can help women with relapsed ovarian cancer feel better and have fewer side effects from treatment.

  Recruiting Phase 2 University College, London · London · NCT05080556

• Combining ZEN003694 and Talazoparib for Recurrent Ovarian Cancer

  This study is testing if combining two cancer drugs, ZEN003694 and talazoparib, can help people with recurrent ovarian cancer feel better after other treatments haven’t worked.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT05071937

• Comparing Niraparib alone versus Niraparib with Bevacizumab for advanced ovarian cancer treatment

  This study is testing whether adding a drug called bevacizumab to the treatment with niraparib can help people with newly diagnosed advanced ovarian cancer do better than with niraparib alone.

  Recruiting at 62 sites Phase 3 AGO Study Group · Amberg and 64 other locations · NCT05009082

• Using a microdevice to measure tumor response in ovarian and related cancers

  This study is testing a tiny device that will be placed in tumors of patients with advanced ovarian and related cancers to see how well different chemotherapy drugs work before surgery.

  Recruiting at 2 sites Phase 1 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT04701645

• Treatment of advanced or metastatic solid tumors with ART0380

  This study is testing a new drug called ART0380 to see if it can safely help people with advanced solid tumors that have specific DNA repair issues, either on its own or with other chemotherapy drugs.

  Recruiting at 62 sites Phase 1/2 Artios Pharma Ltd · Birmingham, Alabama and 87 other locations · NCT04657068

• Investigating the safety and effectiveness of REGN5668 with other drugs for advanced ovarian and uterine cancers

  This study is testing if a new drug called REGN5668, used with other medications, can safely help people with advanced ovarian or uterine cancers.

  Recruiting at 27 sites Phase 1/2 Regeneron Pharmaceuticals · Duarte, California and 27 other locations · NCT04590326

• Evaluating ZN-c3 for patients with ovarian cancer

  This study is testing a new treatment called ZN-c3 combined with other chemotherapy drugs to see if it is safe and effective for people with advanced ovarian cancer.

  Recruiting at 12 sites Phase 1 K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Aurora, Colorado and 34 other locations · NCT04516447

• Surgery and Niraparib for recurrent ovarian cancer

  This study is testing whether surgery followed by chemotherapy and a drug called Niraparib can help people with recurrent ovarian cancer do better than just chemotherapy alone.

  Recruiting Phase 2 Shanghai Gynecologic Oncology Group · Shanghai, Shanghai Municipality and 4 other locations · NCT03983226

• Collecting specimens and data for early detection and prevention of ovarian cancer

  This study is trying to find better ways to detect and prevent ovarian cancer early by collecting blood and tissue samples from people at high risk.

  Recruiting Northwestern University · Chicago, Illinois · NCT00005095

Related topics

Quick answers

How many Fallopian Tube Cancer clinical trials are recruiting right now?

47, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 39 countries. The most sites are in United States (29 trials), China (10 trials), Spain (8 trials), South Korea (8 trials), France (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 17, Phase 1: 8, Phase 1/2: 7, Phase 3: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →